Bempedoic Acid
Bempedoic acid 180 mg film-coated tablets (Nilemdo®) and bempedoic acid 180 mg plus ezetimibe 10 mg film-coated tablets (Nustendi®) are reimbursed on the Community Drug Schemes from 1st September 2024. A Managed Access Protocol (MAP) is in place for bempedoic acid 180 mg film-coated tablets (Nilemdo®) and bempedoic acid 180 mg plus ezetimibe 10 mg film-coated tablets (Nustendi®). This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of bempedoic acid 180 mg film-coated tablets (Nilemdo®) and bempedoic acid 180 mg plus ezetimibe 10 mg film-coated tablets (Nustendi®) under the Community Drug Schemes.
GPs and hospital prescribers, once user-registered with the HSE-Primary Care Reimbursement Service (PCRS), will be authorised to submit an application on an individual patient basis, through the special drug request (SDR) section on the ‘GP Application Suite’ or under ‘Services for Hospitals’ on the PCRS website. A separate application for reimbursement approval must be submitted for each individual.
A copy of the MAP for bempedoic acid 180 mg film-coated tablets (Nilemdo®) and bempedoic acid 180 mg plus ezetimibe 10 mg film-coated tablets (Nustendi®) can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.